Us Bancorp \De\ Myovant Sciences Ltd. Transaction History

Us Bancorp \De\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$11.6 - $20.44 $1,948 - $3,433	168 New	168 $3,000
Q1 2022 May 11, 2022	SELL	$11.38 - $16.4 $785 - $1,131	-69 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$14.31 - $23.87 $4,636 - $7,733	-324 Reduced 82.44%	69 $1,000
Q3 2021 Nov 10, 2021	SELL	$18.94 - $26.99 $814 - $1,160	-43 Reduced 9.86%	393 $9,000
Q2 2021 Aug 05, 2021	BUY	$17.07 - $24.56 $734 - $1,056	43 Added 10.94%	436 $10,000
Q4 2020 Feb 04, 2021	SELL	$13.8 - $27.62 $22,176 - $44,385	-1,607 Reduced 80.35%	393 $11,000
Q2 2020 Aug 07, 2020	BUY	$7.34 - $20.84 $14,680 - $41,680	2,000 New	2,000 $41,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.